Publications
News
FDA grants Fast Track status to Siolta Therapeutics lead clinical program
Fast Track Designation
Read More
News
Siolta Therapeutics expands its executive advisory team
Welcome to Dr. John Martin former CEO/Chairperson of Gilead
Read More
Publications
Nature Microbiology
Elevated faecal 12,13-diHOME concentration in neonates at high risk for asthma is produced by gut bacteria and impedes immune tolerance
Read More
Publications
Nature Microbiology
Elevated faecal 12,13-diHOME concentration in neonates at high risk for asthma is produced by gut bacteria and impedes immune tolerance
Read More
News
Inspiring young scientists in collaboration with California Life Sciences Institute (CLSI)
3rd Annual Biotech Week at SFUSD
Read More
News
Siolta joins coalition to support the advancement of science-driven microbial therapeutics
Microbiome Therapeutic Innovation Group (MTIG)
Read More